Follistatin 344

What it is

Follistatin is a glycoprotein expressed in nearly all tissues that binds and neutralizes members of the TGF-beta superfamily, including activin and myostatin (GDF-8) S6. Because myostatin normally limits muscle growth, increasing follistatin activity — whether by adding the protein or by genetic means — has produced increases in muscle mass in animal models S3S6. The label "Follistatin 344" (FS-344) refers to a follistatin form of 344 amino acids used as the coding sequence in follistatin gene-therapy research; the gene-transfer construct studied in humans is described as rAAV1.CMV.huFollistatin344, delivering the follistatin gene directly into muscle S4. It is a protein/gene product, not a small-molecule drug.

Marketed as

Online "research peptide" vendors market injectable Follistatin 344 to bodybuilding and physique audiences for muscle growth and reduced body fat, framed as a myostatin inhibitor. WADA notes that although no approved follistatin pharmaceutical exists, follistatin is readily purchasable from internet suppliers marketed for "research purposes," creating an accessible doping pathway S2. These are gray-market items, not authorized medicines.

Regulatory status (US)

There is no approved follistatin product; WADA states that no approved pharmaceutical formulations exist S2. Human clinical experience is limited to investigational gene therapy: an early-phase trial (NCT01519349) delivered follistatin gene transfer to a small group of patients with Becker muscular dystrophy and sporadic inclusion body myositis, enrolling 15 participants and completing around 2017 S4. Products sold as research peptides are unapproved and unregulated for human use.

Around the world

Follistatin remains an investigational and preclinical agent internationally rather than a marketed medicine, with follistatin-based approaches studied in various neuromuscular disease models S3. A related follistatin-based fusion protein, ACE-083, has been investigated for neuromuscular conditions, illustrating that the broader follistatin pathway is under formal drug development even though follistatin 344 itself is not an approved therapy S6. No jurisdiction is documented here as having approved follistatin 344 for consumer or performance use.

Evidence

The scientific rationale rests on myostatin blockade. A peer-reviewed review describes follistatin as one of the more potent myostatin antagonists and a candidate therapy for muscle-wasting disease, with the evidence base concentrated in animal and early translational work S3. In primates, regulating follistatin via gene therapy resulted in muscle growth and increases in strength S6. Human evidence is thin and early: the muscular-dystrophy/myositis gene-therapy trial was a small, dose-escalating safety study rather than a definitive efficacy trial, and its interpretation has been debated in the literature S3S4. No injectable follistatin 344 peptide product has demonstrated efficacy in controlled human trials.

Anti-doping

Follistatin is prohibited in sport. Under the WADA Prohibited List, section S4.3 (Agents Preventing Activin Receptor IIB Activation) bans myostatin inhibitors, expressly including myostatin-binding proteins such as follistatin S1. WADA has developed detection strategies because most black-market follistatin lacks the glycosylation of natural human follistatin — it is often produced in E. coli — allowing laboratories to distinguish illicit from endogenous forms, with reported detection limits as low as 0.1 ng/mL in urine S2. Gene-based delivery of follistatin also intersects with WADA's gene-doping provisions; the precise applicable section should be confirmed against the current List S1.

Safety

Safety data in healthy people are essentially absent. The known human exposure comes from a small, monitored gene-therapy study, not from the injectable gray-market peptides now sold online S4. A major, documented hazard is product identity: of 17 black-market follistatin products analyzed, only 9 actually contained follistatin, and others contained unrelated peptides such as MGF and GHRP-2, creating unknown health risks S2S5. Chronic suppression of the myostatin/activin pathway has not been characterized for long-term safety in non-diseased populations S3. Anyone evaluating this space should recognize that an unapproved, unregulated product of uncertain contents carries risks that education cannot quantify.

What's changing

Interest continues in follistatin-pathway biology for muscle-wasting conditions, and analytical anti-doping methods for detecting follistatin doping are maturing S2S3. The gap between legitimate, formally regulated follistatin-pathway drug development and the unregulated gray-market "Follistatin 344" peptide remains wide, and the reliability of what is sold under that name stays a central open concern S5. Readers should re-check the current annual WADA List and the trial literature, as classifications and evidence are updated over time S1S3.